Literature DB >> 10933909

Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.

M A Curran1, S M Kaiser, P L Achacoso, G P Nolan.   

Abstract

Second- and third-generation three-plasmid vector systems, termed FELIX, were constructed from feline immunodeficiency virus (FIV). To enhance vector production, the weak FIV long terminal repeat promoter was replaced with the human cytomegalovirus enhancer/promoter. To construct a minimal system in which Gag-Pol was the only viral protein present, the cytoplasmic transport element was used in place of the FIV Rev-RRE system to facilitate nuclear export of Gag-Pol and the transfer vector. Unconcentrated vector titers routinely exceeded 1 x 10(6) IU/mL for most constructs tested. Second- and optimized third-generation vectors were capable of efficiently infecting G1/S- and G2/M-arrested cells. FIV-based FELIX vectors transduced human dendritic cells, hepatocytes, and aortic smooth muscle with efficiencies similar to that of a control 3T3 cell line. All three of these primary cell types were transducible by both the second- and third-generation FELIX vectors, demonstrating that FIV Gag-Pol alone contains the determinants necessary for transduction of primary cells. In cross-packaging tests, we observed that HIV Gag-Pol does not substantially package FIV vectors; consequently, use of such vectors in human immunodeficiency virus-infected cells should not lead to efficient mobilization of the inserted gene. Thus, this FIV-based vector system offers high efficiency and stable delivery of genes to numerous nondividing and primary cell types, opening new avenues for biological inquiry into normal human cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933909     DOI: 10.1006/mthe.1999.0007

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.

Authors:  Amy Mendenhall; Jacob Lesnik; Chandreyee Mukherjee; Travis Antes; Ranjita Sengupta
Journal:  J Vis Exp       Date:  2012-04-08       Impact factor: 1.355

3.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

4.  Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.

Authors:  Carole Crozet; Yea-Lih Lin; Clément Mettling; Chantal Mourton-Gilles; Pierre Corbeau; Sylvain Lehmann; Véronique Perrier
Journal:  J Cell Sci       Date:  2004-10-19       Impact factor: 5.285

5.  Effective transduction of primary mouse blood- and bone marrow-derived monocytes/macrophages by HIV-based defective lentiviral vectors.

Authors:  Lingbing Zeng; Shiming Yang; Chengxiang Wu; Linbai Ye; Yuanan Lu
Journal:  J Virol Methods       Date:  2006-01-20       Impact factor: 2.014

6.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

7.  Dual-modality gene reporter for in vivo imaging.

Authors:  P Stephen Patrick; Jayne Hammersley; Louiza Loizou; Mikko I Kettunen; Tiago B Rodrigues; De-En Hu; Sui-Seng Tee; Robin Hesketh; Scott K Lyons; Dmitry Soloviev; David Y Lewis; Silvio Aime; Sandra M Fulton; Kevin M Brindle
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-17       Impact factor: 11.205

8.  Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.

Authors:  Dyana T Saenz; Wulin Teo; John C Olsen; Eric M Poeschla
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 9.  Human gene therapy vectors derived from feline lentiviruses.

Authors:  Román A Barraza; Eric M Poeschla
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.